Last reviewed · How we verify
NCT07152756
Impact of a One-Week Discontinuation of Semaglutide on Gastric Retention and Endoscopic Mucosal Visibility Scores
trial testing Esophagogastroduodenoscopy in Gastric Retention in 418 participants. Not yet recruiting.
15 September 2028
Quick facts
| Lead sponsor | Fudan University |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 418 |
| Start date | 15 September 2025 |
| Primary completion | 15 September 2028 |
| Estimated completion | 15 September 2028 |
| Sites | 1 location across China |
Drugs / interventions tested
- Esophagogastroduodenoscopy
Conditions studied
- Gastric Retention — all drugs for Gastric Retention →
Sponsor
Fudan University
Who can join
18 and older, any sex, with Gastric Retention. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A prospective, single-center, observational study to compare the risk of gastric retention and endoscopic mucosal visibility between the exposure group (one-week discontinuation of semaglutide before EGD) and non-exposure group (no semaglutide use before EGD)
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07152756
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Esophagogastroduodenoscopy
Trials testing the same drug.
- NCT06557733 — An Investigational Drug (TPST-1495) in Patients With Familial Adenomatous Polyposis · Phase 2 · recruiting
- NCT07156591 — Impact of Neuropathy on the Risk of Semaglutide-Induced Gastric Retention · not yet recruiting
- NCT06408220 — Risk Assessment Evaluation for Identifying Participants at High Risk for Stomach Cancer · NA · recruiting
- NCT06269380 — Evaluation of Antral Biopsies Obtained in Normal Esophagogastroduodenoscopy · NA · completed
- NCT04939051 — Obeticholic Acid for Prevention in Barrett's Esophagus · Phase 2 · recruiting
Other recruiting trials for Gastric Retention
Currently open trials in the same condition.
- NCT07251803 — GLP1 Fasting Status and Gastric Retention Using Gastric Ultrasound · recruiting
Other Fudan University trials
Trials by the same sponsor.
- NCT06196671 — Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer · Phase 2 · not yet recruiting
- NCT07423611 — ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer · Phase 2 · not yet recruiting
- NCT07410559 — Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Bre · Phase 2 · not yet recruiting
- NCT07490119 — Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer · Phase 2 · not yet recruiting
- NCT07497919 — A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07152756 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fudan University
- Last refreshed: 3 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07152756.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing